The Angelman Syndrome Alliance Grant

The Angelman Syndrome Alliance (ASA) has announced its sixth scientific call for proposals, the ASA Grant 2026, to support research into Angelman Syndrome. The ASA is a nonprofit organization registered in the Netherlands and formed by a partnership of international organizations dedicated to improving the lives of people affected by Angelman Syndrome. Its mission is to foster collaboration across countries and scientific fields in order to accelerate progress toward new treatments and better understanding of this rare genetic disorder. This initiative is designed to strengthen global research efforts by providing resources to investigators in any country who are committed to advancing basic science relevant to Angelman Syndrome. Angelman Syndrome is a rare neurodevelopmental condition caused by loss of UBE3A gene activity. It is characterized by intellectual disability, lack of speech, impaired motor coordination, epilepsy, sleep disturbances, and distinct behavioral features. The ASA emphasizes the need for research addressing the genetic and molecular processes that underlie the disorder, which will lay the foundation for innovative therapeutic approaches. By issuing this international grant call, the ASA aims to attract proposals that explore scientific strategies to better assess, measure, and intervene in UBE3A dysfunction and its associated pathways. The ASA Grant 2026 welcomes applications from researchers worldwide, without geographic restriction. Proposals should focus on basic science research that has the potential to advance understanding of Angelman Syndrome and ultimately inform the development of treatments. Suggested but not exclusive areas of interest include developing biomarkers to measure UBE3A activity in the brain, creating objective clinical outcome measures using technologies such as wearables, defining phenotypes in human or mouse neuronal models, and addressing gaps in preclinical mouse studies. Applications proposing alternative but scientifically relevant directions will also be considered. Applicants may request up to €120,000, with a maximum project duration of three years. Projects may be of shorter length depending on the proposed design and goals. The ASA requires interim reporting when 50% of the project timeline has been reached, followed by a comprehensive final report upon completion. Researchers are also expected to present their findings at the ASA’s biannual conferences, ensuring knowledge dissemination to the broader community of scientists, clinicians, and advocates. The program is designed to support rigorous research that will meaningfully advance knowledge about Angelman Syndrome. The application period opens on June 1, 2025, and closes on November 1, 2025. Applicants will be notified of funding decisions on April 1, 2026, with successful projects beginning on April 1, 2026. Applications must include a cover letter, a full research proposal, curriculum vitae and biographical sketches of the principal investigator and collaborators, and a lay abstract. Proposals must also specify start and end dates, planned duration, and a detailed budget. Applications are submitted directly through the ASA website portal. Only proposals that meet submission requirements and applicable legal and ethical regulations in the applicant’s country of research will be eligible for funding. Questions regarding the application process should be directed to Mrs. Lara Chappell at Lara.Chappell@angelmanalliance.eu. Questions concerning scientific aspects of the research may be directed to Prof. Hanoch Kaphzan, member of the ASA Scientific Advisory Board, at hkaphzan@univ.haifa.ac.il. All applicants are required to review the ASA standard research funding agreement available online before submission. With its global scope and emphasis on rigorous basic science, the ASA Grant 2026 offers researchers an important opportunity to contribute to transformative progress in Angelman Syndrome research.

Ensure ethical/legal approvals in place and align proposal with ASA research priorities.